Clinicopathological significance of CD133 in lung cancer: A meta‑analysis

Tan,Yaoxi; Chen,Bo; Xu,Wei; Zhao,Weihong; Wu,Jianqing

doi:10.3892/mco.2013.195

Clinicopathological significance of CD133 in lung cancer: A meta‑analysis

Authors:
- Yaoxi Tan
- Bo Chen
- Wei Xu
- Weihong Zhao
- Jianqing Wu
View Affiliations

Affiliations: Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: September 30, 2013 https://doi.org/10.3892/mco.2013.195
Pages: 111-115

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD133 is one of the most commonly used markers of lung cancer stem cells (CSCs), which are characterized by their ability for self‑renewal and tumorigenicity. However, the clinical value and significance of CD133 in lung cancer remains controversial. Due to the limited size of the individual studies, the association between CD133 and the clinicopathological characteristics of lung cancer had not been fully elucidated. A meta‑analysis based on published studies was performed with the aim of evaluating the effect of CD133 on the clinicopathological characteristics of lung cancer and to investigate the role of CSCs in the prognosis of lung cancer. A total of 15 eligible studies were included in this meta‑analysis and our results indicated that a positive CD133 expression was significantly associated with poor differentiation and lymph node metastasis, although it was not associated with tumor stage or histological type. Therefore, CD133 may be considered as a prognostic maker of lung cancer. Further clinical studies, with larger patient samples, unified methods and cut‑off levels to detect CD133 expression, classified by tumor stage, therapeutic schedule, follow‑up time and survival events, are required to determine the role of CD133 in clinical application and the association between CD133 and the prognosis of lung cancer.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 60:277–300. 2010.
2.	Alberg AJ, Ford JG and Samet JM; American College of Chest Physicians: Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132(Suppl 3): S29–S55. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Dontu G, Liu S and Wicha MS: Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 1:207–213. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Donnenberg VS and Donnenberg AD: Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Toyooka S, Mitsudomi T, Soh J, et al: Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg. 59:527–537. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
7.	Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T and Moriwaki H: Characterization of CD133⁺ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 351:820–824. 2006.
8.	Ferrandina G, Bonanno G, Pierelli L, et al: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 18:506–514. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Kojima M, Ishii G, Atsumi N, Fujii S, Saito N and Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Janikova M, Skarda J, Dziechciarkova M, et al: Identification of CD133⁺/nestin⁺ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 154:321–326. 2010.
12.	Cui F, Wang J, Chen D and Chen YJ: CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep. 25:701–708. 2011.PubMed/NCBI
13.	Bertolini G, Roz L, Perego P, et al: Highly tumorigenic lung cancer CD133⁺ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 106:16281–16286. 2009.PubMed/NCBI
14.	Xu YH, Wang JM, Zhang GB and Hu HC: Expression and clinical significance of CD133 and B7-H4 in non-small cell lung cancer. Jiangsu Med J. 4:412–415. 2011.
15.	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 50:1088–1101. 1994. View Article : Google Scholar : PubMed/NCBI
18.	Cortes-Dericks L, Galetta D, Spaggiari L, Schmid RA and Karoubi G: High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Eur J Cardiothorac Surg. 41:e173–e181. 2012. View Article : Google Scholar
19.	Herpel E, Jensen K, Muley T, et al: The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer Res. 31:4491–4500. 2011.PubMed/NCBI
20.	Tirino V, Camerlingo R, Franco R, et al: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 36:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Li H, Wang Y, Yu L and Zhao P: Clinicopathological significance of expression of CD133 protein in neuroendocrine lung carcinoma tissues. Chin J Cancer Prev Treat. 18:29–31. 2011.
22.	Li F, Zeng H and Ying K: The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol. 28:1458–1462. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Shien K, Toyooka S, Ichimura K, et al: Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 77:162–167. 2012. View Article : Google Scholar : PubMed/NCBI
24.	Rivera C, Rivera S, Loriot Y, Vozenin MC and Deutsch E: Lung cancer stem cell: new insights on experimental models and preclinical data. J Oncol. 2011:5491812011. View Article : Google Scholar : PubMed/NCBI
25.	Woo T, Okudela K, Mitsui H, et al: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol. 4:32–42. 2010.PubMed/NCBI
26.	Wei YP, Wang M, Hua P, et al: Expression of tumor stem cell marker CD133 in non-small cell lung carcinoma and its clinical significance. J Sun Yat-Sen Univ (Med Sci). 29:312–316. 2008.
27.	Yao J, Wang ZG, Tong XW, Li ZJ and Yu ZG: Expression of tumor stem cell marker CD133 and CD44 in original tumor tissues and metastatic lymph nodes of lung cancer. Med J Natl Defend Force Southwest China. 20:1300–1303. 2010.
28.	Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J and Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer. 126:950–958. 2010.PubMed/NCBI
29.	Lin X, Liu S, Liu N, Yang X, Xu H and Wang E: Expression and significance of stem cell markers CK19, Notch3, CD133, P75NTR, STRO-1 and ABCG2 in pulmonary squamous carcinomas. Zhongguo Fe. 12:316–321. 2009.(In Chinese).
30.	Gu YP, Sun MM, Gu LQ, Zhang H and Xie F: Expression and significance of cancer stem cell marker CD133, ABCG2 and p75NTR in non-small cell lung carcinoma. Suzhou Univ J Med Sci. 30:513–516. 2010.
31.	Cheng JR, Wang SQ, Zu MRT and Zou J: Expressions of CD133 and CD105 in lung cancer tissue and their clinical significance. Tumor. 30:334–337. 2010.
32.	Sun HY, Yang M, Zheng MJ, Ren ZJ and Liu H: Expression of CD133 and ALDH1 in non-small cell lung cancer and their clinical significance. J Clin Exp Pathol. 28:813–815. 2012.
33.	Xu LZ and Yang WT: The criteria of immunohistochemical reaction results. China Oncol. 6:229–231. 1996.